Empagliflozin reduced the risk of cardiovascular events and hospitalization for heart failure compared to DPP-4 inhibitors in people with type 2 diabetes
Treatment with the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (Jardiance, Boehringer Ingelheim/Eli Lilly) significantly reduces the risk of cardiovascular death or ...
The EMPEROR-Preserved trial of empagliflozin (Jardiance; Boehringer Ingelheim/Eli Lilly) met its primary endpoint, according to top-line results released today, meaning a therapy with specif..查看文章
The EMPEROR-Preserved Phase III trial met its primary endpoint and demonstrated significant risk reduction with empagliflozin for the composite of cardiovascular death or hospitalization for..查看文章
Interim analysis of the EMPRISE real-world evidence study showed that empagliflozin was associated with a reduced risk in all-cause mortality, hospitalization for heart failure and acute kid..查看文章
EMPAGLIFLOZIN TO BE INVESTIGATED AS A POSSIBLE TREATMENT FOR COVID-19 IN RECOVERY TRIAL * MAIN AIM IS TO ASSESS WHETHER EMPAGLIFLOZIN REDUCES RISK OF DEATH AMONG PATIENTS ADMITTED TO HOSPITA..查看文章
empagliflozin与发音含义,同义词,反义词,翻译,刑和更多的